miR-155 in cancer drug resistance and as target for miRNA-based therapeutics.
about
Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy.Enhancer control of miR-155 expression in Epstein-Barr virus infected B cellsCircular RNA Complement Factor H (CFH) Promotes Glioma Progression by Sponging miR-149 and Regulating AKT1miRNAs and lncRNAs as Predictive Biomarkers of Response to FOLFOX Therapy in Colorectal CancermiR-34a Regulates Multidrug Resistance via Positively Modulating OAZ2 Signaling in Colon Cancer Cells
P2860
miR-155 in cancer drug resistance and as target for miRNA-based therapeutics.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
miR-155 in cancer drug resistance and as target for miRNA-based therapeutics.
@en
miR-155 in cancer drug resistance and as target for miRNA-based therapeutics.
@nl
type
label
miR-155 in cancer drug resistance and as target for miRNA-based therapeutics.
@en
miR-155 in cancer drug resistance and as target for miRNA-based therapeutics.
@nl
prefLabel
miR-155 in cancer drug resistance and as target for miRNA-based therapeutics.
@en
miR-155 in cancer drug resistance and as target for miRNA-based therapeutics.
@nl
P2860
P1476
miR-155 in cancer drug resistance and as target for miRNA-based therapeutics.
@en
P2093
Katrien Van Roosbroeck
Recep Bayraktar
P2860
P2888
P356
10.1007/S10555-017-9724-7
P577
2017-12-27T00:00:00Z
P6179
1100077322